Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth

ZD1839 (“Iressa”) is an orally active, selective epidermal growth factor (EGF) receptor‐tyrosine kinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with HSP90 antagonist, 17‐AAG in malignant human glioma cell lines. ZD1839 independently produced a dose‐dependent inhibitio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular carcinogenesis 2006-05, Vol.45 (5), p.288-301
Hauptverfasser:	Premkumar, Daniel R., Arnold, Beth, Pollack, Ian F.
Format:	Artikel
Sprache:	eng
Schlagworte:	17-AAG Antineoplastic Combined Chemotherapy Protocols - therapeutic use apoptosis Apoptosis - drug effects Benzoquinones Caspase 3 Caspases - metabolism cell cycle Cell Proliferation - drug effects Drug Combinations Enzyme Activation - drug effects epidermal growth factor Fibroblasts - metabolism Fibroblasts - pathology G1 Phase - drug effects glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology heat shock protein inhibitor Humans Iressa Lactams, Macrocyclic Lung - metabolism MAPK Mitogen-Activated Protein Kinases - metabolism PI3K Poly(ADP-ribose) Polymerases - metabolism Proto-Oncogene Proteins c-akt - metabolism Quinazolines - administration & dosage Receptor, Epidermal Growth Factor - antagonists & inhibitors Rifabutin - administration & dosage Rifabutin - analogs & derivatives Signal Transduction - drug effects Synergy Tumor Stem Cell Assay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!